About AM-pharma

AM-Pharma’s purpose is to save the lives of patients confronted with kidney disease, sepsis and organ injury. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary recombinant human alkaline phosphatase has the potential to become the first treatment specifically developed for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.


At AM-Pharma, we strive to improve the quality of life for patients with kidney disease, sepsis and organ injury, initially focusing on saving the lives of patients with sepsis-associated acute kidney injury (SA-AKI).

Our investors